Summary
Genetic variations that are related to clopidogrel metabolism did not diminish clopidogrel efficacy in patients with acute coronary syndromes or atrial fibrillation, according to new data from the Clopidogrel in Unstable Angina to Prevent Recurrent Events [CURE] and Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events [ACTIVE] trials.
- Myocardial Infarction
- Cardiology Genomics
- Arrhythmias
- © 2010 MD Conference Express
Tools
CURE ACTIVE: No Loss of Clopidogrel Efficacy with the CYP2C19 Loss-of-Function Allele in Patients with ACS or AF
Permalink:
Table of contents
Cited By...
- No citing articles found.